Abstract
The cytoplasmic serine/threonine kinase BRAF and receptor tyrosine kinases of the platelet-derived growth factor receptor (PDGFR) family are frequently activated in cancer by mutations of an equivalent amino acid. Structural studies have provided important insights into why these very different kinases share similar oncogenic hot spots and why the PDGFR juxtamembrane region is also a frequent oncogenic target. This research has implications for other kinases that are mutated in human tumours and for the treatment of cancer using kinase inhibitors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pollock, P. M. & Meltzer, P. S. Lucky draw in the gene raffle Nature 417, 906–907 (2002).
Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
Mercer, K. E. & Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25–50 (2003).
Yang, S. H., Sharrocks, A. D. & Whitmarsh, A. J. Transcriptional regulation by the MAP kinase signalling cascades. Gene 320, 3–21 (2003).
Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 595–602 (2003).
Wan, P. T. C. et al. Mechanism of activation of the RAF–ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855–867 (2004).
Furitsu, T. et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukaemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92, 1736–1744 (1993).
Glover, H. R., Baker, D. A., Celetti, A. & Dibb, N. J. Selection of activating mutations of c-fms in FDC-P1 cells. Oncogene 11, 1347–1356 (1995).
Yeung, Y. -G. & Stanley, E. R. Proteomic approaches to the analysis of early events in colony-stimulating factor-1 signal transduction. Mol. Cell. Proteomics 2, 1143–1155.
Lev, S., Blechman, J. M., Givol, D. & Yarden, Y. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit. Rev. Oncog. 5, 141–168 (1994).
Heldin, C. H. & Westermark, B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol. Rev. 79, 1283–1316 (1999).
Stirewalt, D. L. & Radich, J. P. The role of FLT3 in haematopoietic malignancies. Nature Rev. Cancer 3, 650–665 (2003).
Ullrich, A. & Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell 61, 203–212 (1990).
Kacinski, B. M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev. 46, 71–74 (1997).
Nagata, H. et al. Identification of a point mutation in the catalytic domain of the proto-oncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci USA 92, 10560–10564 (1995).
Reilly, J. T. Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. 116, 744–757 (2002).
Hirota, S. et al. Gain of function mutations of c-kit in human gastrointestinal stromal tumours. Science 279, 577–580 (1998).
Kemmer, K. et al. KIT mutations are common in testicular seminomas. Am. J. Pathol. 164, 305–313 (2004).
Hirota, S. et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumours. Gastroenterology 125, 660–667 (2003).
Heinrich, M. C. et al. PDGFRA activating mutations in gastrointestinal stromal tumours. Science 299, 708–710 (2003).
Kitayama, H. et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85, 790–798 (1995).
Johnson, L. N., Noble, M. E. M. & Owen, D. J. Active and inactive protein kinases: structural basis for regulation. Cell 85, 149–158 (1996).
Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912–1934 (2002).
Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275–282 (2002).
Knighton, D. R., et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253, 407–414 (1991).
Hubbard, S. R., Ellis, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746–754 (1994).
Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5573–5581 (1997).
Pautsch, A. et al. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure 9, 955–965 (2001).
Munshi, S. et al. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. J. Biol. Chem. 277, 38797–38802 (2001).
Mol, C. D. et al. Structure of a c-Kit product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278, 31461–31464 (2003).
Mol, C. D. et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279, 31655–31663.
Yamaguchi, H. & Hendrickson, W. A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 348, 484–489 (1996).
Schindler, T. et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell 3, 639–648 (1999).
Yang, J. et al. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. Nature Struct. Biol. 9, 940–944 (2002).
Yang, J. et al. Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. Mol. Cell 9, 1227–1240 (2002).
Wang, Z., Harkins, P. C., Ulevitch, R. J., Cobb, M. H. & Goldsmith, E. J. The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc. Natl Acad. Sci. USA 94, 2327–2332 (1997).
Bellon, S., Fitzgibbon, M. J., Fox, T. & Hsiao, H. M. & Wilson K. P. The structure of phosphorylated p38γ is monomeric and reveals a conserved activation-loop conformation. Structure Fold Des. 7, 1057–1065 (1999).
Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H. & Goldsmith, E. J. Activation mechanism of the MAP Kinase ERK2 by dual phosphorylation. Cell 90, 859–869 (1997).
Engh, R. A. & Bossenmeyer, D. Structural aspects of protein kinase control — role of conformational flexibility. Pharmacol. Ther. 93, 99–111 (2002).
De Bondt, H. et al. Crystal structure of cyclin-dependent kinase 2. Nature 363, 595–602 (1993).
Jeffrey, P. D. et al. Mechanism of CDK activation revealed by the structure of a cyclin-A CDK2 complex. Nature 376, 313–320 (1995).
Lowe, E. D. et al. Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41, 15625–15634 (2002).
Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nature Rev. Cancer 1, 222–231 (2001).
Russo, A. A., Jeffrey, P. D. & Pavletich, N. P. Structural basis of cyclin-dependent kinase activation by phosphorylation. Nature Struct. Biol. 3, 696–700 (1996).
Stamos, J., Sliwkowski, M. X. & Eigenbrot, C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277, 46265–46272 (2002).
Schindler, T., Bornmann, W., Pellicena, P, Miller, W. T., Clarkson, B. & Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938–1942 (2000).
Bohmer, F. D. et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J. Biol. Chem. 278, 5148–5155 (2003).
Zhang, B. H. & Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429–5439 (2000).
Chan, P. M., Ilangumaran, S., La Rose, J., Chakrabartty, A. & Rottapel, R. Autoinhibition of the Kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol. Cell. Biol. 23, 3067–3078 (2003).
Wybenga-Groot, L. et al. Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745–757 (2001).
Li, S., Covino, N. D., Stein, E. G., Till, J. H. & Hubbard, S. R. Structural and biochemical evidence for an autoinhibitory role for tyrosine 984 in the juxtamembrane region of the insulin receptor. J. Biol. Chem. 278, 26007–26014 (2003).
Huse, M., Chen, Y. -G., Massague, J. & Kuriyan, J. Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96, 425–436 (1999).
Griffith, J. et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13, 169–178 (2004).
Morley, G. M., Uden, M., Gullick, W. J. & Dibb, N. J. Cell specific transformation by c-fms activating loop mutations is attributable to constitutive receptor degradation. Oncogene 18, 3076–3084 (1999).
Ma, Y. et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99, 1741–1744 (2002).
Longley, B. J., Reguera, M. J. & Ma, Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk. Res. 25, 571–576 (2001).
Zermati, Y. et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasm. Oncogene 22, 660–664 (2003).
Moriyama, Y. et al. Role of aspartic acid 814 in the function and expression of c-kit receptor tyrosine kinase. J. Biol. Chem. 271, 3347–3350 (1996).
Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56, 100–104 (1996).
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR–ABL tyrosine kinase in chronic myeloid leukaemia. N. Engl. J. Med. 344, 1031–1037 (2001).
Joensuu, H. et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 3, 655–664 (2002).
Skorski, T. Oncogenic tyrosine kinases and the DNA-damage response. Nature Rev. Cancer 2, 351–360 (2002).
Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139–145 (2000).
Apperley, J. F. et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β. N. Engl. J. Med. 347, 481–487 (2002).
Pietras, K., Sjoblom, T., Rubin, K., Heldin, C. -H. & Ostman, A. PDGF receptors as cancer drug targets. Cancer Cell 3, 439–443 (2003).
Shah, N. P. et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukaemia. Cancer Cell 2, 117–125 (2002).
Gambacorti-Passerini, C. B. et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol. 4, 75–85 (2003).
Harrison, S. C. Variation on an Src-like theme. Cell 112, 737–740 (2003).
Azam, M., Latek, R. R. & Daley, G. Q. Mechanisms of autoinhibition and STI-571/Imatinib resistance revealed by mutagenesis of BCR–ABL. Cell 112, 831–843 (2003).
Papa, F. R., Zhang, C., Shokat, K. & Walter, P. Bypassing a kinase activity with an ATP-competitive drug. Science 302, 1533–1537 (2003).
Hubbard, S. R. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr. Opin. Struct. Biol. 12, 735–741 (2002).
Nagar, B. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112, 859–871 (2003).
Sawyers, C. L. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukaemia. Cancer Cell 1, 413–415 (2002).
Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony stimulating factor 1 promotes progression of mammary tumours to malignancy. J. Exp Med. 193, 727–740 (2001).
Murray, L. J. et al. SU11248 inhibits tumor growth and CSF-1R dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Mestastasis 20, 757–766 (2003).
Bardelli, A. et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300, 949 (2003).
Robertson, S. C., Tynan, J. A. & Donoghue, D. J. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet. 16, 265–271 (2000).
Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004)
Paez, J. G. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004).
Eisenberg, D. The discovery of the α-helix and β-sheet, the principal structural features of proteins. Proc. Natl Acad. Sci. USA 100, 11207–11210 (2003).
Ma, Y. et al. Inhibition of spontaneous receptor phosphorylation by residues in a putative α-helix in the KIT intracellular region. J. Biol. Chem. 274, 13399–13402 (1999).
Antonescu, C. R. et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behaviour: KIT analysis and clinical correlates of 120 gastrointestinal stromal tumours. Clin. Cancer Res. 9, 3329–3337 (2003).
Lasota, J., Jasinski, M., Sarlomo-Rikala, M. & Miettinen, M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumours and do not occur in leiomyomas or leiomyosarcomas. Am. J. Pathol. 154, 53–60 (1999).
Hou, Y. Y. et al. C-kit gene mutation in human gastrointestinal stromal tumours. World J. Gastroenterol. 10, 1310–1324 (2004).
Rubin, B. P. et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61, 8118–8121 (2001).
Acknowledgements
This work was supported by the Biotechnology and Biological Sciences Research Council. We thank D. Barford, T. Gibson, R. Marais and J. Taylor for many helpful comments.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dibb, N., Dilworth, S. & Mol, C. Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat Rev Cancer 4, 718–727 (2004). https://doi.org/10.1038/nrc1434
Issue Date:
DOI: https://doi.org/10.1038/nrc1434